Comparative Pharmacology
Head-to-head clinical analysis: HYDROCODONE BITARTRATE versus QDOLO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCODONE BITARTRATE versus QDOLO.
HYDROCODONE BITARTRATE vs QDOLO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocodone is an opioid agonist that binds to mu-opioid receptors in the central nervous system, inhibiting ascending pain pathways and altering pain perception.
Tramadol is a centrally acting synthetic opioid analgesic. It binds to μ-opioid receptors and inhibits norepinephrine and serotonin reuptake.
Adults: 5-10 mg orally every 4-6 hours as needed for pain; maximum 60 mg/day.
Oral: 50-100 mg every 4-6 hours as needed for pain; maximum 400 mg per day. Immediate-release tablets only. Extended-release formulations require different dosing and are not interchangeable.
None Documented
None Documented
Terminal elimination half-life is approximately 3.5-4 hours in healthy adults. In patients with hepatic impairment (Child-Pugh Class B), half-life may be prolonged to ~6 hours. In renal impairment (CrCl <30 mL/min), half-life may be extended by 30-50%.
Terminal elimination half-life approximately 2-4 hours in adults; prolonged to 4-6 hours in elderly and up to 12-16 hours in severe renal impairment (CrCl <30 mL/min)
Renal excretion of metabolites (primarily hydromorphone and norhydrocodone) accounts for approximately 99% of elimination, with less than 1% excreted unchanged. Biliary/fecal elimination is negligible.
Renal 90% (60% unchanged, 30% as glucuronide conjugate), fecal 10%
Category D/X
Category C
Opioid Agonist
Opioid Agonist